Our findings in AS align well with earlier results from studies of risk stratification following RP, thus indicating that DNA ploidy and PTEN may be used as biomarkers throughout the stages of PCa development and their different clinical handling. This evidence concerns the gene PTEN and posterior cortical atrophy.